How potent is potent? Evaluation of sexual function and bother in men who report potency after treatment for prostate cancer: data from CaPSURE.
about
Let's rethinking about the safety of phosphodiesterase type 5 inhibitor in the patients with erectile dysfunction after radical prostatectomySerial personal digital assistant data capture of health-related quality of life: a randomized controlled trial in a prostate cancer clinic.Personal digital assistant data capture: the future of quality of life measurement in prostate cancer treatment.Millon Behavioral Medicine Diagnostic (MBMD) Predicts Health-Related Quality of Life (HrQoL) over time among men treated for localized prostate cancer.Among potent men post radical prostatectomy, does the need for phosphodiesterase inhibitors have an impact on sexual bother scores?When 'dueling technologies' are mistaken for progress.Potency preservation following stereotactic body radiation therapy for prostate cancer.Assessing couples' preferences for postoperative sexual rehabilitation before radical prostatectomy.Changes in specific domains of sexual function and sexual bother after radical prostatectomy.Association of stress management skills and perceived stress with physical and emotional well-being among advanced prostrate cancer survivors following androgen deprivation treatment.Can sexual bother after radical prostatectomy be predicted preoperatively? Findings from a prospective national study of the relation between sexual function, activity and bother.Prostate cancer and QOL: impact of treatment, disease burden and psychosocial interventions.
P2860
Q26740135-299B4212-B281-4EC6-ABA6-257876BBAB52Q31117971-7B805A1B-24CB-4FA1-961A-9D64F85811A1Q33698919-F2F7D285-8A1E-4C62-9E6B-0730FA7B9753Q35141974-196AC4F7-66F7-4CB2-9337-BE7CDDF01319Q35785290-93D1C270-FDF0-4E95-8303-9C351AD2F07BQ37876958-639C3426-03FB-4917-9E61-8DAC3E5C4031Q38158080-588A6141-2C0A-4205-9F02-E75560AB46C7Q45742064-9B8F572D-A67E-41FB-90D7-4F31D8EBA47EQ46386497-2B3E8290-1D20-464F-9993-1E4AB3BF39F9Q48423110-DD3829E1-BCC4-495F-ACC2-BF310664A9B5Q50783389-E446FE6A-B495-499A-97DD-E11601624E7BQ52596131-94C3DAF3-2F28-485C-9EC9-9169FA5D90DD
P2860
How potent is potent? Evaluation of sexual function and bother in men who report potency after treatment for prostate cancer: data from CaPSURE.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
How potent is potent? Evaluati ...... ate cancer: data from CaPSURE.
@ast
How potent is potent? Evaluati ...... ate cancer: data from CaPSURE.
@en
type
label
How potent is potent? Evaluati ...... ate cancer: data from CaPSURE.
@ast
How potent is potent? Evaluati ...... ate cancer: data from CaPSURE.
@en
prefLabel
How potent is potent? Evaluati ...... ate cancer: data from CaPSURE.
@ast
How potent is potent? Evaluati ...... ate cancer: data from CaPSURE.
@en
P2093
P1433
P1476
How potent is potent? Evaluati ...... ate cancer: data from CaPSURE.
@en
P2093
Deborah P Lubeck
Gary D Grossfeld
Peter R Carroll
Shilpa S Mehta
Theresa M Koppie
P304
P356
10.1016/S0090-4295(02)02118-0
P407
P577
2003-01-01T00:00:00Z